Licenses of 18 pharma firms cancelled for manufacturing drugs

 Licenses of 18 pharma firms cancelled for manufacturing drugs

The Government of India canceled the licenses of 18 pharma companies for manufacturing spurious and substandard medicines. These companies have been asked to stop manufacturing. This order has come under action against pharma companies making fake medicines and poor quality medicines. The Drugs Controller General of India (DCGI) had inspected many pharmaceutical companies.

Central and state teams conducted surprise inspections in 20 states and then this action was taken. Official sources gave this information on Tuesday. Strict action is going on against the pharma companies across the country related to the manufacture of spurious medicines. The campaign is going on for about 15 days.

Action taken in these states

During this, action has been taken on 70 companies in Himachal Pradesh, 45 in Uttarakhand and 23 in Madhya Pradesh. These raids have been done in the midst of reports of deaths and diseases caused by Indian medicines from many countries. Last month, Gujarat-based pharma company Zydus Lifesciences recalled over 55,000 bottles of a generic drug used to treat gout from the US market. The drug failed the impurity specifications.

Complaints were being received against Indian companies

Apart from this, three employees of a pharmaceutical firm in Noida were arrested after the death of 18 children allegedly due to cough syrup in Uzbekistan last year. He was accused of making and selling adulterated medicine. At the same time, in the month of February itself, a Chennai-based pharmaceutical company had recalled the consignment of eye drops. The US Food and Drug Administration issued a warning not to buy or use Azricare eye drops because of possible infection.

Must Read: Global Recycling Day: From waste to innovation! Here’s how Audi is turning old car parts into new vehicles

Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOKINSTAGRAMand TWITTER.